The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join about 15 other drugmakers that count as the industry’s biggest, and include other giants like Johnson & Johnson, Merck, and Novartis. And while it’s an